Am J Transplant, Volume 21, Suppl 3 Archives - Page 138 of 139 - ATC Abstracts

2021 American Transplant Congress
Use of a Novel Bead-based Assay to Measure the Impact of Imlifidase on ABO IgG Antibodies
A. Halpin¹, B. Motyka², T. Ellis², J. Pearcey², T. L. Lowary³, A. Runström⁴, L. Winstedt⁴, R. Bockermann⁴, S. Järnum⁴, A. Robertson⁴, L. J. West⁵
¹Department of Pediatrics and Laboratory Medicine and Pathology, University of Alberta and Alberta Precision Laboratories, Edmonton, AB, Canada, ²Department of Pediatrics, University of Alberta, Edmonton, AB, Canada, ³Department of Chemistry, University of Alberta, Edmonton, AB, Canada, ⁴Hansa Biopharma, Lund, Sweden, ⁵Department of Pediatrics and Laboratory Medicine and Pathology, University of Alberta, Edmonton, AB, Canada
*Purpose: The accurate assessment and measurement of ABO antibodies (ABO-Ab) is a critical component of ABO-incompatible (ABOi) transplantation. ABO-Ab comprise both IgG and IgM, which…
2021 American Transplant Congress
Belatacept Exposure Not Associated With Rejection. Can Doses be Lowered without Compromising Efficacy?
M. McGowan¹, A. Bickenbach¹, B. Miyagawa², A. Christianson¹, T. Mizuno², P. West-Thielke³, J. Leone⁴, E. Woodle¹, D. Kaufman⁵, A. Wiseman⁶, A. Matas⁷, A. Vinks², R. Alloway¹
¹U Cincinnati, Cincinnati, OH, ²Cincinnati Children's Med Center, Cincinnati, OH, ³U Illinois, Chicago, IL, ⁴Tampa Gen, Tampa, FL, ⁵U Wisconsin, Madison, OH, ⁶Centura Transplant, Denver, CO, ⁷U Minnesota, Minneapolis, MN
*Purpose: Phase 1 and 2 belatacept(BELA) pharmacokinetic(PK) studies informed dosing in phase 3 studies. PK data from these studies revealed higher BELA troughs on Day…
2021 American Transplant Congress
Safety of Sars-cov-2 Mrna Vaccines in Solid Organ Transplant Recipients
M. Ou, B. Boyarsky, J. Motter, R. Greenberg, A. Teles, J. Ruddy, M. Krach, W. Werbel, R. Avery, A. Massie, D. Segev, J. Garonzik-Wang
Johns Hopkins School of Medicine, Baltimore, MD
*Purpose: The safety of SARS-CoV-2 mRNA vaccines in solid organ transplant recipients (SOTRs) remains unknown. We investigated adverse events in SOTRs who received these mRNA…
2021 American Transplant Congress
Sequential Analysis of Renal Allograft Rejection at Single Cell Resolution
T. Shi¹, C. Castro-Rojas¹, A. Burg¹, K. Roskin¹, J. Rush², B. Haraldsson², A. Shields³, R. Alloway³, E. Woodle³, D. Hildeman¹
¹Immunobiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Novartis Pharmaceuticals AG, Basel, Switzerland, ³University of Cincinnati Medical Center, Cincinnati, OH
*Purpose: Renal allograft anti-rejection therapies (corticosteroids (CCS) and anti-lymphocyte globulin) have been the primary treatment modalities for over six decades, yet little is known about…
2021 American Transplant Congress
A Phase 1 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of At-1501
S. Perrin¹, A. Gill², C. Gill², P. Gustafson¹
¹Novus Therapeutics, Irvine, CA, ²ALS Therapy Development Institute, Cambridge, MA
*Purpose: Execute a phase 1 study of AT-1501 to assess safety, pharmacokinetics, and functional activity.*Methods: The study employed a placebo-controlled, sequential, dose-escalation design. 28 healthy…
2021 American Transplant Congress
Pediatric Donation During COVID-19 Pandemic
M. MacConmara, B. Wang, L. de Gregorio, J. Shah, D. Desai, S. Hanish, P. Vagefi, C. S. Hwang
Surgery, UT Southwestern Medical Center, Dallas, TX
*Purpose: The COVID-19 pandemic led to a decrease in transplantation throughout the United States. We examined the impact of the pandemic in regards to the…
2021 American Transplant Congress
Results of the APP Practice Survey: Do APPs Practice at the Top of Their Scope of Practice?
H. Domingo¹, D. Krieger², B. Muth³, A. Frank⁴, A. Borth⁵, H. McDade⁵, K. Paolini⁶, A. Mayfield⁵, M. Siegfired⁷, J. Yoo⁸, H. Hoy⁹, N. McCormick¹⁰
¹Northwestern University, Chicago, IL, ²University of California-San Francisco, San Francisco, CA, ³University of Wisconsin, Madison, WI, ⁴Medstar Georgetown University, Annandale, VA, ⁵University of Maryland, Baltimore, MD, ⁶Erie County Medical Center, Grand Island, NY, ⁷Swedish Organ Transplant, Seattle, WA, ⁸Rush University, Chicago, IL, ⁹University of Alabama - Huntsville, Huntsville, AL, ¹⁰University of Colorado-Denver, Denver, CO
*Purpose: Transplant centers employ Advance Practice Providers (APPs) in response to physician trainee work hour restrictions and to increase patient access to transplant care. APPs…
2021 American Transplant Congress
Risk Classification Models for Kidney Graft Failure
M. G. Naik¹, K. Budde¹, D. Telmo Neves²
¹Medical Department, Division of Nephrology and Internal Intensive Care Medicine, Charité, Berlin, Germany, ²Intelligent Analytics for Massive Data, German Research Center for Artificial Intelligence, Berlin, Germany
*Purpose: Longterm graft survival after kidney transplantation is stagnant over the last decades. An individual risk assessment for graft failure is needed. In our project…
2021 American Transplant Congress
Gm2a: A Novel Regulatory Pathway Controlling Alloimmunity
K. M. Baecher¹, P. S. Heeger², P. Cravedi², M. Fribourg², M. L. Ford¹
¹Department of Surgery, Emory University, Atlanta, GA, ²Mount Sinai School of Medicine, New York, NY
*Purpose: In recently published studies we discovered that the inhibitory receptor FcγRIIB regulates CD8+ T cell alloimmunity in a cell-autonomous fashion, and that increased expression…
2021 American Transplant Congress
The Trifecta Study: Calibrating Circulating Donor-Derived Cell-Free DNA at the Time of Indication Biopsies Against the Molecular Phenotype of the Biopsy Reveals a Prominent Association with NK Cell Genes
P. Halloran¹, Z. Demko², A. Prewett², J. Reeve¹, P. Billings²
¹Alberta Transplant Applied Genomics Centre, Edmonton, AB, Canada, ²Natera Inc., San Carlos, CA
*Purpose: The international, multicenter, prospective Trifecta study was designed to calibrate dd-cfDNA% measurements in blood at the time of indication biopsy against the molecular characteristics…